BCLI Stock Price, BrainStorm Cell Therapeutics Quote, Chart

Market Summary

USD0.530.00

Market Closed

0.00%

BCLI Stock Price

View Fullscreen

BCLI RSI Chart

BCLI Valuation

Market Cap

36.2M

Price/Earnings (Trailing)

-2.11

Price/Free Cashflow

-1.77

BCLI Price/Sales (Trailing)

BCLI Profitability

Return on Equity

353.89%

Return on Assets

-408.56%

Free Cashflow Yield

-56.53%

BCLI Fundamentals

BCLI Earnings

Earnings (TTM)

-17.2M

Earnings Growth (Yr)

-11.16%

Earnings Growth (Qtr)

-354.98%

Breaking Down BCLI Revenue

Last 30 days

-11.7%

Last 90 days

65.6%

Trailing 12 Months

-81.7%

How does BCLI drawdown profile look like?

BCLI Financial Health

Current Ratio

0.24

BCLI Investor Care

Shares Dilution (1Y)

77.63%

Diluted EPS (TTM)

-0.41

Tracking the Latest Insider Buys and Sells of BrainStorm Cell Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 19, 2024	lebovits chaim	acquired	7,798	0.5199	15,000	president & ceo
Apr 18, 2024	lebovits chaim	acquired	60,470	0.5255	115,072	president & ceo
Apr 17, 2024	lebovits chaim	acquired	70,941	0.5457	130,000	president & ceo
Mar 11, 2024	yablonka uri	acquired	-	-	109,426	evp & chief business officer
Mar 11, 2024	lebovits chaim	acquired	-	-	305,198	president & ceo
Mar 11, 2024	lindborg stacy	acquired	-	-	241,935	co-chief executive officer
Mar 11, 2024	patlis alla	acquired	-	-	65,246	see remarks
Sep 01, 2023	lindborg stacy	bought	20,402	1.7741	11,500	co-chief executive officer
Aug 02, 2023	lebovits chaim	acquired	-	-	31,185	president & ceo
Aug 02, 2023	lindborg stacy	acquired	-	-	35,000	co-chief executive officer

Which funds bought or sold BCLI recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Professional Financial Advisors, LLC	unchanged	-	5,040	9,757	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	2,000	2,000	-%
Apr 25, 2024	Bank of New York Mellon Corp	unchanged	-	3,498	6,772	-%
Apr 24, 2024	Zullo Investment Group, Inc.	sold off	-100	-4,399	-	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	reduced	-1.73	32,645	64,254	-%
Apr 19, 2024	CALDWELL SUTTER CAPITAL, INC.	unchanged	-	-	-	-%
Apr 19, 2024	Westside Investment Management, Inc.	unchanged	-	58.00	112	-%
Apr 17, 2024	Cranbrook Wealth Management, LLC	new	-	565	565	-%
Apr 16, 2024	Weaver Consulting Group	unchanged	-	58,153	112,577	0.04%
Apr 15, 2024	KINGSWOOD WEALTH ADVISORS, LLC	new	-	45,768	45,768	-%

Are Funds Buying or Selling BCLI?

Are funds buying BCLI calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own BCLI

No. of Funds

Unveiling BrainStorm Cell Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 12, 2024	ness kevin dean	6.25%	3,060,000	SC 13G/A
Apr 05, 2023	ness kevin dean	9.98%	3,660,000	SC 13G/A
Feb 14, 2022	abbhi investments, llc	6.69%	2,425,853	SC 13G
Feb 04, 2022	ness kevin dean	9.1%	3,300,000	SC 13G
Jul 12, 2021	blackrock inc.	1.3%	474,347	SC 13G/A
Feb 02, 2021	blackrock inc.	6.1%	1,920,340	SC 13G
May 08, 2020	daly joseph patrick	3.66%	1,077,500	SC 13D/A
Apr 08, 2020	abbhi investments, llc	9.03%	2,367,751	SC 13D
Mar 18, 2020	abbhi investments, llc	9.03%	2,367,751	SC 13G
Nov 21, 2019	daly joseph patrick	4.58%	1,035,181	SC 13D

Recent SEC filings of BrainStorm Cell Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	4	Insider Trading
Apr 22, 2024	3	Insider Trading
Apr 19, 2024	4	Insider Trading
Apr 17, 2024	8-K	Current Report
Apr 11, 2024	8-K	Current Report
Apr 09, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Apr 02, 2024	424B5	Prospectus Filed
Apr 01, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report

Peers (Alternatives to BrainStorm Cell Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.4B	2.5B	-8.70%	-12.49%	74.73	6.21	13.74%	186.89%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

BrainStorm Cell Therapeutics Inc News

Latest updates

BrainStorm Cell Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-25.9%	4.00	6.00	6.00	8.00	8.00	13.00	19.00	26.00	29.00	35.00	42.00	49.00	51.00	33.00	19.00	18.00	7.00	8.00	9.00	12.00	11.00
Current Assets	23.4%	2.00	2.00	1.00	3.00	3.00	8.00	13.00	19.00	23.00	28.00	35.00	41.00	43.00	30.00	17.00	15.00	3.00	5.00	6.00	8.00	10.00
Cash Equivalents	21.5%	1.00	1.00	1.00	2.00	1.00	4.00	9.00	15.00	19.00	26.00	31.00	36.00	38.00	25.00	12.00	12.00	1.00	2.00	1.00	3.00	1.00
Net PPE	-8.8%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Liabilities	9.7%	9.00	8.00	10.00	13.00	11.00	12.00	11.00	11.00	10.00	10.00	12.00	12.00	16.00	7.00	9.00	9.00	19.00	15.00	13.00	12.00	6.00
Current Liabilities	23.4%	8.00	6.00	8.00	10.00	9.00	9.00	8.00	7.00	6.00	6.00	8.00	8.00	11.00	6.00	9.00	8.00	18.00	12.00	11.00	8.00	6.00
Shareholder's Equity	-Infinity%	-4.86	-	-	-	-3.01	1.00	8.00	14.00	19.00	25.00	30.00	36.00	35.00	26.00	10.00	9.00	-	-	-	0.00	5.00
Retained Earnings	-2.7%	-215	-209	-208	-202	-197	-192	-185	-178	-173	-167	-162	-155	-149	-137	-132	-125	-117	-109	-103	-99.05	-94.02
Additional Paid-In Capital	1.6%	210	207	204	198	195	194	194	193	193	192	192	192	185	163	143	134	105	103	99.00	98.00	95.00
Shares Outstanding	33.5%	60.00	45.00	41.00	38.00	37.00	36.00	36.00	36.00	36.00	36.00	36.00	36.00	35.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	-	-	-	93.00	-	-	-	120	-	-	-	278	-	-	-	75.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	48.7%	-3,285	-6,409	-6,778	-3,986	-4,648	-4,850	-6,134	-3,688	-5,508	-6,460	-5,329	-8,968	-7,578	-6,924	-5,662	-15,029	-3,278	-3,626	-3,508	-835	-3,723
Cashflow From Investing	1733.3%	196	-12.00	4.00	2,005	1,038	-11.00	-12.00	-17.00	-1,297	1,696	-39.00	-37.00	-302	-86.00	-2,070	-1,994	-345	1,439	1,391	3,131	3,968
Cashflow From Financing	-52.8%	3,352	7,097	5,299	3,230	-	-	-	-	-34.00	-106	-	7,109	20,939	19,627	7,414	28,958	2,064	3,156	5.00	-	-

BCLI Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development, net (Note 12)	$ 10,746	$ 13,956
General and administrative	10,693	10,866
Operating loss	(21,439)	(24,822)
Financial income (expense), net	(447)	545
Gain on change in fair value of Warrants liability (Note 9)	4,694
Net loss	$ (17,192)	$ (24,277)
Basic net loss per share	$ (0.40)	$ (0.66)
Diluted net loss per share	$ (0.40)	$ (0.66)
Weighted average number of shares outstanding used in computing basic net loss per share	43,075,938	36,509,060
Weighted average number of shares outstanding used in computing diluted net loss per share	43,075,938	36,509,060

BCLI Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 1,300	$ 772
Short-term deposit (Note 8)		2,211
Other accounts receivable	51	91
Prepaid expenses and other current assets (Note 4)	548	32
Total current assets	1,899	3,106
Long-Term Assets:
Prepaid expenses and other long-term assets	22	23
Restricted Cash	185	0
Operating lease right of use asset (Note 5)	1,416	4,389
Property and Equipment, Net (Note 6)	686	933
Total Long-Term Assets	2,309	5,345
Total assets	4,208	8,451
Current Liabilities:
Accounts payables	4,954	6,224
Accrued expenses	1,240	84
Operating lease liability (Note 5)	603	1,427
Employees related liability	1,003	1,065
Total current liabilities	7,800	8,800
Long-Term Liabilities:
Operating lease liability (Note 5)	672	2,666
Warrants liability (Note 9)	594	0
Total long-term liabilities	1,266	2,666
Total liabilities	9,066	11,466
Stockholders' Deficit:
Stock capital: (Note 10)	13	12
Additional paid-in-capital	210,258	194,910
Treasury stocks	(116)	(116)
Accumulated deficit	(215,013)	(197,821)
Total stockholders' deficit	(4,858)	(3,015)
Total liabilities and stockholders' deficit	$ 4,208	$ 8,451

About BrainStorm Cell Therapeutics Inc

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.

CEO	Mr. Chaim Lebovits
WEBSITE	brainstorm-cell.com
INDUSTRY	Biotechnology
EMPLOYEES	44

BrainStorm Cell Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for BrainStorm Cell Therapeutics Inc? What does BCLI stand for in stocks?

BCLI is the stock ticker symbol of BrainStorm Cell Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BrainStorm Cell Therapeutics Inc (BCLI)?

As of Fri Apr 26 2024, market cap of BrainStorm Cell Therapeutics Inc is 36.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCLI stock?

You can check BCLI's fair value in chart for subscribers.

What is the fair value of BCLI stock?

You can check BCLI's fair value in chart for subscribers. The fair value of BrainStorm Cell Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of BrainStorm Cell Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BCLI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is BrainStorm Cell Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether BCLI is over valued or under valued. Whether BrainStorm Cell Therapeutics Inc is cheap or expensive depends on the assumptions which impact BrainStorm Cell Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCLI.

What is 5 year return on BrainStorm Cell Therapeutics Inc's stock?

In the past 10 years, BrainStorm Cell Therapeutics Inc has provided -0.19 (multiply by 100 for percentage) rate of return.